BTCC
/
BTCC Square
/
Global Cryptocurrency
/
United Therapeutics Stock Surges 40% on Positive Phase 3 Trial Results
United Therapeutics Stock Surges 40% on Positive Phase 3 Trial Results
11
2
BTCCSquare news:
United Therapeutics (UTHR) shares soared 40% following the announcement of successful Phase 3 clinical trial results for its nebulized Tyvaso Inhalation Solution. The study demonstrated significant improvement in forced vital capacity for idiopathic pulmonary fibrosis patients, with consistent results across all subgroups.
CEO Martine Rothblatt hailed the achievement as a testament to scientific innovation addressing critical patient needs. The company plans to submit a supplemental New Drug Application to the FDA, potentially expanding Tyvaso's approved indications.
By:
